Compare LMRI & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMRI | BIOA |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.7M | 681.9M |
| IPO Year | N/A | N/A |
| Metric | LMRI | BIOA |
|---|---|---|
| Price | $7.41 | $16.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $20.75 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 946.9K | 354.1K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.35 | $720.93 |
| Revenue Next Year | $5.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.45 | $3.79 |
| 52 Week High | $19.45 | $24.00 |
| Indicator | LMRI | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 33.62 | 42.51 |
| Support Level | $7.23 | $15.74 |
| Resistance Level | $10.53 | $19.01 |
| Average True Range (ATR) | 0.81 | 1.31 |
| MACD | -0.27 | -0.16 |
| Stochastic Oscillator | 18.82 | 30.46 |
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities including MRIs, CT scans, PET scans, X-rays, ultrasounds, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated from the Outpatient segment, which generates revenue by performing imaging studies and providing radiologists' interpretations of those studies.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.